XML 15 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 28, 2019
Dec. 28, 2018
 [1]
Current assets:    
Cash and cash equivalents $ 369,789 $ 314,775
Short-term investments 452,328 378,559
Trade receivables, net 97,541 162,771
Other receivables 12,390 16,056
Inventory, net 12,352 9,838
Prepaid expenses and other current assets 12,847 15,017
Total current assets 957,247 897,016
Long-term investments 337,785 157,187
Long-term restricted cash and investments 1,100 1,100
Property and equipment, net 50,709 50,897
Operating lease right-of-use assets 16,573 5,867
Deferred tax assets, net 210,237 244,111
Goodwill 63,684 63,684
Other long-term assets 5,763 2,424
Total assets 1,643,098 1,422,286
Current liabilities:    
Accounts payable 12,274 10,901
Accrued clinical trial liabilities 23,709 18,231
Accrued compensation and benefits 24,144 32,142
Rebates and fees due to customers 17,273 14,954
Accrued collaboration liabilities 7,847 7,419
Current portion of deferred revenue 321 0
Other current liabilities 25,228 21,825
Total current liabilities 110,796 105,472
Long-term portion of lease liabilities 22,543 12,178
Long-term portion of deferred revenue 16,632 15,897
Other long-term liabilities 4,495 1,286
Total liabilities 154,466 134,833
Commitments
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 302,784,854 and 299,876,080 at June 30, 2019 and December 31, 2018, respectively 303 300
Additional paid-in capital 2,211,668 2,168,217
Accumulated other comprehensive income (loss) 2,207 (701)
Accumulated deficit (725,546) (880,363)
Total stockholders’ equity 1,488,632 1,287,453
Total liabilities and stockholders’ equity $ 1,643,098 $ 1,422,286
[1]
The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.